Nils Krüger
Dr. Nils Krüger is a prominent researcher affiliated with Brigham and Women’s Hospital and a founding member of the Mass General Brigham healthcare system. He specializes in cardiology and has made significant contributions to understanding heart failure, particularly in patients with obesity and type 2 diabetes. His recent study, presented at the European Society of Cardiology annual conference, highlighted the potential of GLP-1 agonists, such as semaglutide and tirzepatide, to dramatically reduce hospitalizations and early death risks among heart failure patients.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United Kingdom | 1 | 8.00 | 0.04% | +0% | 67,886,011 | 28,133 | $2,700,000 | 1,119$ |
| Totals | 1 | 67,886,011 | 28,133 | $2,700,000 | 1,119$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United Kingdom:
Dr Nils Krüger, of Brigham and Women’s hospital, is a study author who discussed the benefits of GLP-1 targeting medications for heart failure patients.
8